Suggested remit: To appraise the clinical and cost effectiveness of duvelisib within its marketing authorisation for treating relapsed or refractory chronic lymphocytic leukaemia.
Status In progress
Process STA 2018
ID number 1083

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
05 May 2021 The appraisal is anticipated to begin during early August 2021
24 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of duvelisib for treating relapsed chronic lymphocytic leukaemia. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
13 August 2020 - 11 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 February 2018 In progress. Topic referred on 22 July 2016

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance